|By PR Newswire||
|February 3, 2014 05:00 PM EST||
OAKLAND, Calif., Feb. 3, 2014 /PRNewswire/ -- Tests that require patients to collect a single stool sample at home and then send it to a lab for analysis will detect about 79 percent of colorectal cancers, according to a new evidence review published in the Annals of Internal Medicine. The review of 19 studies examining eight different fecal immunochemical tests, known as "FITs," also finds that the tests will correctly identify about 94 percent of patients who do not have cancers of the rectum or colon.
"We know the FIT is easy to use, and now we also know that it is a great tool for assessing which patients have cancer and which patients don't," said Beth Liles, MD, review co-author and clinical investigator at the Kaiser Permanente Center for Health Research in Portland, Ore.
Colorectal cancer is the second leading cause of cancer death in the United States, according to the Centers for Disease Control and Prevention. Yet one in three adults is not adequately screened.
"FIT is simple, can be done at home, and can save lives," said Jeffrey Lee, MD, MAS, the study's lead author and post-doctoral researcher at the Kaiser Permanente Division of Research in Oakland, Calif. and University of California, San Francisco. "The American Cancer Society and other professional organizations have recommended FIT as a screening tool for colorectal cancer since 2008, but there are still many people who don't know about it."
The U.S. Preventive Services Task Force recommends that people with normal risk for colorectal cancer should begin screening at age 50 and stop at age 75. Unlike older stool tests, FIT does not require people to restrict their diets or to stop taking medications. Conducted annually, the test detects small amounts of blood in the stool, and people who test positive are much more likely to have colorectal cancer. People who have a positive FIT need a follow-up colonoscopy to look for cancer or pre-cancerous polyps.
Other screening options for colorectal cancer include sigmoidoscopy, which involves physical examination of the lower colon, recommended every five years; or colonoscopy, which examines the entire colon, every 10 years.
The evidence review, funded by the National Institutes of Health, found that the FITs were fairly sensitive. On average, the tests detected 79 percent, or about 4 of 5 cancers with only one round of testing. The tests were also highly specific: on average, 94 percent of people who did not have cancer tested negative with a single FIT.
By comparison, studies indicate that another at-home test called fecal occult blood test (also known as FOBT) detects only about 13 percent to 50 percent of cancers after a single round of testing. The FOBT is the predecessor to FIT and requires three stool samples as well as medication and dietary restrictions.
According to the evidence review, no single FIT performed markedly better than another, but the authors caution that there was only one study comparing brands head-to-head. Most of the FITs required collection of only one stool sample. Surprisingly, the authors found that brands requiring two or three stool samples were no more accurate than those requiring only one sample.
The 19 studies reviewed included between 80 and 27,860 patients, with the average age ranging from 45 to 63. Study settings varied, but all included patients with no symptoms of colorectal cancer. In 12 of the studies, all patients took the FIT and received a colonoscopy. In seven studies, patients only had a colonoscopy to follow-up on a positive FIT. Approximately two years later, researchers followed up with patients who had had a negative FIT to determine whether they had been diagnosed with colorectal cancer.
This research is part of Kaiser Permanente's ongoing efforts to promote prevention and evidence-based care. Last year Kaiser Permanente researchers found that patients who visited their doctor for any reason were nearly six times more likely to get screened for colon cancer compared to those who didn't visit their doctor.
The review was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institute, and the NCI consortium Population-Based Research Optimizing Screening through Personalized Regimens (T32DK007007, U24 CA171524 and U54 CA163262).
Authors include: Jeffrey K. Lee, MD, MAS, Kaiser Permanente Division of Research, Oakland, Calif. and University of California, San Francisco; Elizabeth G. Liles, MD, MCR, Kaiser Permanente Center for Health Research, Portland, Ore.; Stephen Bent, MD, University of California, San Francisco; and Theodore Levin, MD, and Douglas A. Corley, MD, PhD, Kaiser Permanente Division of Research, Oakland, Calif.
About the Kaiser Permanente Division of Research
The Kaiser Permanente Division of Research conducts, publishes and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. It seeks to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR's 550-plus staff is working on more than 250 epidemiological and health services research projects. For more information, visit www.dor.kaiser.org or follow us on Twitter @KPDOR.
About the Kaiser Permanente Center for Health Research
The Kaiser Permanente Center for Health Research, founded in 1964, is a nonprofit research institution dedicated to advancing knowledge to improve health. It has research sites in Portland, Ore., Honolulu and Atlanta. http://www.kpchr.org
About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 9.1 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share.
SOURCE Kaiser Permanente
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Aug. 28, 2016 03:30 AM EDT Reads: 2,323
Aug. 28, 2016 02:00 AM EDT Reads: 1,761
Aug. 28, 2016 01:45 AM EDT Reads: 2,140
Aug. 28, 2016 01:30 AM EDT Reads: 2,069
Aug. 28, 2016 01:00 AM EDT Reads: 2,960
Aug. 28, 2016 12:15 AM EDT Reads: 1,819
Aug. 27, 2016 11:00 PM EDT Reads: 3,994
Aug. 27, 2016 08:45 PM EDT Reads: 2,342
Aug. 27, 2016 08:45 PM EDT Reads: 1,774
Aug. 27, 2016 06:15 PM EDT Reads: 737
Aug. 27, 2016 06:00 PM EDT Reads: 3,093
Aug. 27, 2016 06:00 PM EDT Reads: 731
Aug. 27, 2016 05:15 PM EDT Reads: 1,579
Aug. 27, 2016 05:00 PM EDT Reads: 1,884
Aug. 27, 2016 04:45 PM EDT Reads: 1,636